Management strategies in alcoholic liver disease - PubMed (original) (raw)
Review
Management strategies in alcoholic liver disease
Herbert Tilg et al. Nat Clin Pract Gastroenterol Hepatol. 2007 Jan.
Abstract
Alcoholic liver disease (ALD) and its complications is still one of the most frequent causes of death in the Western world. Treatment modalities for both alcoholic steatohepatitis (ASH; the major inflammatory complication of ALD) and alcoholic liver cirrhosis are insufficient. Severe ASH is associated with a high mortality; although glucocorticoid treatment has been reported to improve survival, meta-analyses of clinical trials performed to date have failed to show a convincing benefit of such an approach. Most of the progress in understanding these diseases, especially ASH, has come from studies of cytokines. Various proinflammatory cytokines, such as tumor necrosis factor (TNF), have been proposed to have an important role in the pathophysiology of ALD and its complications. Pilot studies on the use of anti-TNF drugs, such as pentoxifylline or infliximab, in the treatment of ASH have now been performed with various levels of success. The treatment of patients with alcohol-related cirrhosis is mainly symptomatic and no therapies are currently available except orthotopic liver transplantation for end-stage liver disease. Independent of the stage of disease, abstinence from alcohol is the cornerstone of management. New treatment modalities for these diseases are eagerly awaited.
Similar articles
- Treatment of alcoholic liver disease.
Day CP. Day CP. Liver Transpl. 2007 Nov;13(11 Suppl 2):S69-75. doi: 10.1002/lt.21336. Liver Transpl. 2007. PMID: 17969070 Review. - Management of alcoholic liver disease.
Lucey MR. Lucey MR. Clin Liver Dis. 2009 May;13(2):267-75. doi: 10.1016/j.cld.2009.02.003. Clin Liver Dis. 2009. PMID: 19442918 - Review article: current management of alcoholic liver disease.
Tome S, Lucey MR. Tome S, et al. Aliment Pharmacol Ther. 2004 Apr 1;19(7):707-14. doi: 10.1111/j.1365-2036.2004.01881.x. Aliment Pharmacol Ther. 2004. PMID: 15043511 Review. - Alcohol-related liver disease: treatment controversies.
Batey RG. Batey RG. Alcohol Alcohol Suppl. 1994;2:327-33. Alcohol Alcohol Suppl. 1994. PMID: 8974352 Review.
Cited by
- Protective effects of hydroxysafflor yellow A (HSYA) on alcohol-induced liver injury in rats.
He Y, Liu Q, Li Y, Yang X, Wang W, Li T, Zhang W, Cui Y, Wang C, Lin R. He Y, et al. J Physiol Biochem. 2015 Mar;71(1):69-78. doi: 10.1007/s13105-015-0382-3. Epub 2015 Jan 28. J Physiol Biochem. 2015. PMID: 25626885 - Pharmacotherapy for alcohol use disorder: current and emerging therapies.
Swift RM, Aston ER. Swift RM, et al. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):122-33. doi: 10.1097/HRP.0000000000000079. Harv Rev Psychiatry. 2015. PMID: 25747925 Free PMC article. Review. - Drinking status of heavy drinkers detected by arrival time parametric imaging using sonazoid-enhanced ultrasonography: study of two cases.
Wakui N, Takayama R, Mimura T, Kamiyama N, Maruyama K, Sumino Y. Wakui N, et al. Case Rep Gastroenterol. 2011 Mar 26;5(1):100-9. doi: 10.1159/000326951. Case Rep Gastroenterol. 2011. PMID: 21503166 Free PMC article. - The effect of Lycium barbarum polysaccharide on alcohol-induced oxidative stress in rats.
Cheng D, Kong H. Cheng D, et al. Molecules. 2011 Mar 17;16(3):2542-50. doi: 10.3390/molecules16032542. Molecules. 2011. PMID: 21415835 Free PMC article. - Mulberry and dandelion water extracts prevent alcohol-induced steatosis with alleviating gut microbiome dysbiosis.
Park S, Kim DS, Wu X, J Yi Q. Park S, et al. Exp Biol Med (Maywood). 2018 Jul;243(11):882-894. doi: 10.1177/1535370218789068. Exp Biol Med (Maywood). 2018. PMID: 30105955 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous